论文部分内容阅读
目的对比观察尼麦角林与吡拉西坦治疗血管性痴呆的临床疗效。方法2007年1月~2009年1月98例血管性痴呆患者随机分为尼麦角林组和吡拉西坦组,每组各49例,对比观察两组的MMSE、WMS、CGI、ADL评分及临床疗效。结果两组治疗后MMSE、WMS评分均明显升高,SI、ADL评分明显下降,与治疗前比较差异有统计学意义(P<0.05)。并且,尼麦角林组治疗后MMSE、WMS、SLADL评分均优于吡拉西坦组治疗后水平,两组比较差异有统计学意义(P<0.05)。尼麦角林组总有效率为89.8%明显高于吡拉西坦组的67.3%,差异有统计学意义(P<0.05)。两组均未发生明显不良反应。结论吡拉西坦与尼麦角林均能有效治疗VD,且尼麦角林的疗效要优于吡拉西坦。
Objective To compare the clinical efficacy of nicergoline and piracetam in the treatment of vascular dementia. Methods From January 2007 to January 2009, 98 patients with vascular dementia were randomly divided into nicergoline group and piracetam group, with 49 cases in each group. The MMSE, WMS, CGI and ADL score were compared between the two groups Clinical efficacy. Results The scores of MMSE and WMS in both groups were significantly increased after treatment, and SI and ADL scores decreased significantly compared with those before treatment (P <0.05). Moreover, MMSE, WMS and SLADL score of nicergoline group were better than those of piracetam group after treatment, the difference was statistically significant (P <0.05). The total effective rate in nicergoline group was 89.8%, which was significantly higher than that in piracetam group (67.3%), the difference was statistically significant (P <0.05). No significant adverse reactions occurred in both groups. Conclusion Both piracetam and nicergoline can effectively treat VD, and nicergoline has better efficacy than piracetam.